BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $594,607 | +64.2% | 8,699 | +96.1% | 0.01% | +60.0% |
| Q2 2023 | $362,029 | +12.9% | 4,435 | +2.6% | 0.01% | +25.0% |
| Q1 2023 | $320,575 | +12.3% | 4,321 | +25.5% | 0.00% | 0.0% |
| Q4 2022 | $285,356 | +16.9% | 3,443 | +300.3% | 0.00% | 0.0% |
| Q3 2022 | $244,000 | -18.7% | 860 | -0.6% | 0.00% | -20.0% |
| Q2 2022 | $300,000 | -20.2% | 865 | +0.1% | 0.01% | 0.0% |
| Q1 2022 | $376,000 | -92.7% | 864 | -91.5% | 0.01% | -92.8% |
| Q4 2021 | $5,170,000 | +59.0% | 10,161 | +51.4% | 0.07% | +35.3% |
| Q3 2021 | $3,252,000 | +25.4% | 6,712 | +16.5% | 0.05% | +10.9% |
| Q2 2021 | $2,593,000 | – | 5,760 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 840,131 | $363,810,000 | 4.80% |
| Montanaro Asset Management Ltd | 89,950 | $38,952,000 | 4.80% |
| Sandhill Capital Partners LLC | 109,939 | $47,608,000 | 4.09% |
| Brown Capital Management | 918,328 | $397,673,000 | 3.96% |
| STONE RUN CAPITAL, LLC | 22,325 | $9,668,000 | 3.57% |
| DF DENT & CO INC | 686,484 | $297,275,000 | 3.42% |
| Westwind Capital | 27,741 | $12,013,000 | 3.23% |
| MAIRS & POWER INC | 657,962 | $284,924,000 | 2.87% |
| Summit Creek Advisors LLC | 58,133 | $25,174,000 | 2.85% |
| Pembroke Management, LTD | 76,250 | $33,019,000 | 2.76% |